- Home
- CLPR vs RFL Comparison
CLPR vs RFL Comparison
Compare CLPR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLPR | RFL |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Real Estate |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 54.4M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPR | RFL |
|---|---|---|
| Price | $3.48 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 67.7K | ★ 142.1K |
| Earning Date | 11-13-2025 | 11-19-2025 |
| Dividend Yield | ★ 11.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,179,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.90 | ★ 43.96 |
| 52 Week Low | $3.37 | $1.17 |
| 52 Week High | $6.49 | $3.19 |
Technical Indicators
Market Signals| Indicator | CLPR | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 66.75 |
| Support Level | $3.38 | $1.45 |
| Resistance Level | $3.55 | $1.60 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 13.33 | 72.09 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.